Scott Smith, Chairman of the Board
Mr. Smith is the founder of GreenRiver BioPharma LLC. Scott has 30 years of biotechnology and pharmaceutical industry experience. Scott is currently serving as President of BioAtla, a company focused on the development of conditionally active biologics (CABs) for the treatment of solid tumor cancers. Prior to that Mr. Smith was at Biotech leader Celgene. In his ten years at Celgene from 2008-2018, his leadership role expanded from Vice President of Global Marketing for Inflammation & Immunology, to Global Head of that division, to President of the Inflammation & Immunology Franchise to his appointment as Celgene’s President and Chief Operating Officer. With a particular emphasis and interest in immunology, Mr. Smith drove the growth of Celgene’s Inflammation and Immunology division from 13 to more than 1,300 people worldwide and oversaw the clinical development, global registration, and commercial success of the blockbuster drug Otezla. Mr. Smith’s prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies, and contributing to regulatory and clinical development strategies.
Mr. Smith also serves on the board of directors of Titan Pharmaceuticals, Triumvira Immunologics and Springbank Pharmaceuticals (Chairman), and Refuge Bio. Scott serves as an advisor to 3eBioVentures, a Beijing based venture capital firm.
Mr. Smith received both his BSc degree in Chemistry and Biology and his HBSc degree in Pharmacology and Toxicology from the University of Western Ontario and his Masters of International Business Management from the American Graduate School of International Management (Thunderbird).
Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm’s Chairman and Chief Executive Officer.
Brian serves on the Board of Directors of Triumvira Immunologics, Appili Therapeutics, Satellos Bioscience, and Qing Bile Therapeutics. Brian is also on the Faculty of Science Dean’s Advisory Board at McMaster University. Brian was formerly the Chairman of the Board of Grey Wolf Animal Health, a member of the Life Sciences Advisory Board at the National Research Council of Canada and on the Boards of BIOTECanada and the Baycrest Foundation.
Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian started his career at New York-based investment banking firms SCO Financial Group and Molecular Securities. Brian received an Honors Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics. Brian is the proud recipient of the McMaster University 2017 Distinguished Alumni Award in Science.
Cynthia (Cindy) Collins, MBA
Ms. Collins was the CEO of Human Longevity, Inc., the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype, and clinical data. Prior to her time at Human Longevity, Inc., Ms. Collins was CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses, and Clarient Diagnostics. She was also the President and CEO of GenVec, Inc., and spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies.
Ms. Collins is a member of the Board of Directors for the Analytical Life Science and Diagnostics Association, Alliance for Regenerative Medicine Foundation, and Cavidi AB, as well as serving as a strategic advisor to Phase Holographic Imaging. Ms. Collins received her BSc degree in Microbiology from the University of Illinois, Urbana, and her MBA from The University of Chicago Booth School of Business.
Jürgen Eckhardt is SVP and Head of Leaps by Bayer, which is the strategic venture capital unit of Bayer. The mission of Leaps is to invest in breakthrough technologies and disruptive business models in the areas of healthcare and agriculture. Jürgen is currently a board member of BlueRock, Joyn Bio, Dewpoint, Khloris, Oerth Bio, Immunitas, and eGenesis. Before joining Bayer in 2016, Jürgen Eckhardt was head of the venture capital franchise at Bellevue Asset Management in Switzerland.
Previously, he was a management consultant and Associate Partner with McKinsey & Co. in Zürich and New York and a member of the Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. Jürgen received his M.D. from the University of Basel and his MBA from INSEAD in Fontainebleau, France.
John Holyoake, Ph.D.
Dr. John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. Dr. Holyoake’s responsibilities include M&A advisory and monetization planning, as well as conducting technical and commercial due diligence of companies across all healthcare sectors. Dr. Holyoake’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a focus on preclinical-stage biotech. He has previous industry experience with the clinical-stage oncology company TenX BioPharma and the life science consulting group SHI Link, as well as with several early-stage life science companies.
In addition to Triumvira, he currently serves on the Board of Directors of Appili Therapeutics and is a member of the Core Evaluation Team for Genome Canada’s Genomic Applications Partnership Program and he also sits on the TOHealth Risk Capital Committee. Dr. Holyoake received his MSc in Biochemistry and Ph.D. from the University of Oxford before coming to North America for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.
Dr. Jak Knowles joined Leaps by Bayer as Vice President of Pharma Ventures in 2018. Prior to joining Bayer, Jak served as CEO of CytoSen Therapeutics, developing Natural Killer cell immunotherapies for oncology indications. Jak co-founded and served as interim-CEO for Exonics Therapeutics in 2016, a CRISPR gene-editing company that was acquired by Vertex in 2019.
In addition to Triumvira Immunologics, Jak currently serves on the Board of Directors for Century Therapeutics, Pyxis Oncology, Metagenomi Technologies, Vesigen Therapeutics, and NewLeaf Symbiotics. Jak received his medical degree from Stanford University and received his B.A. in Biology from Binghamton University.
Paul Lammers, MD, MSc
Dr. Paul Lammers joined Triumvira Immunologics as President and Chief Executive Officer on January 1, 2018. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company for whom he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, both from Federal and State grants and leading traditional and strategic venture firms. He also brought the company public on the NASDAQ exchange.
Previously, Dr. Lammers briefly served as President of Repros Therapeutics (NASDAQ: RPRX) in The Woodlands, Texas. Before Repros Therapeutics, he served 6 years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of the German Pharmaceutical company, Merck KgA. Throughout his 30 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, as well as a small public and privately held biotech companies. He started his pharmaceutical career at Organon in the Netherlands, after obtaining both biology and medical degrees, and moved with his family to the US in 1992.
Dr. Lammers is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of CME programs for medical scientists and healthcare professionals. He currently serves on ImmunoMet’s Board of Directors.